CAPS Medical

Executive Summary

CAPS Medical is an Israeli med-tech company pioneering PlasmaSure™, a minimally invasive catheter-based platform that delivers non-thermal atmospheric plasma to solid tumors. The technology aims to selectively ablate cancer cells while preserving surrounding healthy tissue, offering a novel approach across a broad range of oncology indications. Founded in 2020, the company is currently in the preclinical stage, focusing on validating its platform for safety and efficacy. With a strong intellectual property foundation and a growing interest in non-invasive cancer treatments, CAPS Medical represents a high-risk, high-reward opportunity. Its unique mechanism of action—using cold atmospheric plasma to induce oxidative stress and apoptosis in tumor cells—differentiates it from thermal ablation and radiation therapies. The company has raised no disclosed funding and operates with a lean team, suggesting a need for additional capital to advance toward first-in-human trials.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data in relevant tumor models35% success
• TBDSeries A funding or strategic partnership to support IND-enabling studies30% success
• TBDRegulatory engagement (e.g., FDA pre-submission meeting) for first-in-human trial design25% success